MANH vs QRVO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MANH exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 71.66%, though it lacks an Altman Z-Score for bankruptcy risk assessment. While the company has a stellar 25-quarter track record of earnings beats, the stock is currently in a severe technical downtrend, losing over 37% of its value in the last six months. The current price of $126.11 trades at a significant premium to both the Graham Number ($20.64) and the growth-based Intrinsic Value ($79.74). Despite a bullish analyst target of $208.55, the combination of slow revenue growth (5.7%) and bearish insider sentiment warrants a neutral stance until price stabilization occurs.
QRVO exhibits strong fundamental health with a Piotroski F-Score of 8/9 and exceptional liquidity (Current Ratio 3.67). While the stock trades above its Graham Number ($57.1), it is significantly undervalued relative to its growth potential, as evidenced by a PEG ratio of 0.19 and an intrinsic value of $107.08. Despite bearish insider sentiment and technical trends, the company's consistent track record of earnings beats over 25 quarters and explosive YoY earnings growth (307%) suggest a strong recovery trajectory.
Compare Another Pair
Related Comparisons
MANH vs QRVO: Head-to-Head Comparison
This page compares Manhattan Associates, Inc. (MANH) and Qorvo, Inc. (QRVO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.